The RAS/RAF/MEK/ERK signalling pathways determine the resistance of melanoma cells to inhibitors used in immunotherapy, which is based on the blocking the checkpoints programmed death-1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA4) by antibodies. This evidence concerns the gene CTLA4 and melanoma.